Ninlaro (Ixazomib) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

Instructions: Please fill out all applicable sections completely and legibly. Attach any additional documentation that is important for the review (e.g., chart notes or lab data, to support the authorization request). Information contained in this form is Protected Health Information under HIPAA.

MEMBER INFORMATION				
LAST NAME:	FIRST NAME:			
PHONE NUMBER:	DATE OF BIRTH:			
STREET ADDRESS:				
CITY:	STATE: ZIP CODE:			
PATIENT INSURANCE ID NUMBER:				
MALE FEMALE HEIGHT (IN/CM): WEIGHT (LB/KG): ALLERGIES:				

IF YOU ARE NOT THE PATIENT OR THE PRESCRIBER, YOU WILL NEED TO SUBMIT A PHI DISCLOSURE AUTHORIZATION FORM WITH THIS REQUEST WHICH CAN BE FOUND AT THE FOLLOWING LINK: <u>PRIMETHERAPEUTICS.COM/NOPP</u>

PATIENT'S AUTHORIZED REPRESENTATIVE (IF APPLICABLE): _______AUTHORIZED REPRESENTATIVE'S PHONE NUMBER: ______

PRESCRIBER INFORMATION				
LAST NAME:	FIRST NAME:			
PRESCRIBER SPECIALTY:	EMAIL ADDRESS:			
NPI NUMBER:	DEA NUMBER:			
PHONE NUMBER:	FAX NUMBER:			
STREET ADDRESS:				
CITY:	STATE: ZIP CODE:			
REQUESTOR (if different than prescriber):	OFFICE CONTACT PERSON:			

MEDICATION OR MEDICAL DISPENSING INFORMATION					
MEDICATION NAME:					
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF THERAPY/REFILLS:	QUANTITY:		
NEW THERAPY		IF RENEWAL: DATE THERAPY	INITIATED:		
DURATION OF THERAPY (SPECIFIC DATES):					

Continued on next page.



Ninlaro (Ixazomib) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:	MEMBER'S FIRST NAME:			
1. HAS THE PATIENT TRIED ANY OTHE	R MEDICATIONS FOR THIS CONDITION?	YES (if yes, complete below) NO		
MEDICATION/THERAPY (SPECIFY	DURATION OF THERAPY (SPECIFY	RESPONSE/REASON FOR		
DRUG NAME AND DOSAGE):	DATES):	FAILURE/ALLERGY:		
,	,			
2. LIST DIAGNOSES:		ICD-10:		
Multiple myeloma				
Other diagnosis:ICD				
	: PLEASE PROVIDE ALL RELEVANT CLINIC	AL INFORMATION TO SUPPORT A		
PRIOR AUTHORIZATION.				
Clinical Information:				
Is patient using requested medication	in conjunction with a clinical trial? Ye	s 🗆 No		
Is patient newly diagnosed multiple n	ıyeloma? □ Yes □ No			
Will patient be using Ninlaro(ixazomil	b) as maintenance for newly diagnosed ı	multiple myeloma? 🗆 Yes 🗆 No		
-	utrophil count (ANC) of at least 500 cells	s/mm3? 🗆 Yes 🗆 No <i>*Please provide</i>		
documentation.				
Does the patient have a platelet coun	t of at least 30,000/mm3? 🗆 Yes 🗆 No *#	Please provide documentation.		
	vious therapy before using Ninlaro (ixazo	omib)?* 🗆 Yes 🗆 No		
*Please provide documentation.				
Will the patient use lenalidomide ANI	D dexamethasone in combination with N	linlaro (ixazomib)? 🗆 Yes 🗆 No		
Will the patient use any other treatment regimen combination other than in combination with lenalidomide AND				
dexamethasone? Yes No				
*Please provide documentation.				
Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the				
physician feels is important to this review?				
Please note: Not all drugs/diagnosis are covered on all plans. This request may be denied unless all required				
information is received.				
ATTESTATION: I attest the information provided is true and accurate to the best of my knowledge. I understand that				
the Health Plan, insurer, Medical Group or its designees may perform a routine audit and request the medical				
information necessary to verify the accuracy of the information reported on this form.				
	-			
Prescriber Signature or Electronic I.D.	Verification:	Date:		
© 2017–2024 Prime Therapeutics Management	LLC, a Prime Therapeutics LLC company			



Revision Date: 4/15/2023

Ninlaro (Ixazomib) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit

Phone: 877-228-7909 Fax: 800-424-7640

CONFIDENTIALITY NOTICE: The documents accompanying this transmission contain confidential health information that is legally privileged. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately (via return FAX) and arrange for the return or destruction of these documents.

FAX THIS FORM TO: 800-424-7640

MAIL REQUESTS TO: Prime Therapeutics Management Prior Authorization Program

Atten: CP-4201 P.O.Box 64811 St. Paul, MN 55164-0811 Phone: 877-228-7909

